title: Prevention. Aspirin in primary prevention--good news and bad news.
abstract: The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.
authors.affiliation: Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Research Park, Boca Raton, FL 33431, USA. chenneke@fau.edu
authors.forename: Charles H
authors.initials: CH
authors.lastname: Hennekens
authors.forename: Colin
authors.initials: C
authors.lastname: Baigent
mesh_terms: D001241:Aspirin / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D006801:Humans; D011322:Primary Prevention; D012307:Risk Factors
chemical_list: D016861:Cyclooxygenase Inhibitors; D001241:Aspirin